\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes SecurityThe European Commission would like to gain a better understanding of successful innovations stemming from the EU-funded security research work programme. To this end, the European Commission has created the Security Innovation Award, intended to recognise an innovator involved in EU-funded security research projects that have achieved significant impact.
Applications are open from now until 31 March at 18h00 UTC.
More details on how to apply via this link.
The award is part of a larger, year-long study commissioned by DG HOME to identify the factors influencing the uptake of EU-Funded security research outcomes. The study results, which will be shared with the EU security R&I community, will ultimately help the Commission and other key stakeholders improve uptake rates and pave the way for innovative technologies from R&I to the market and to security operations.
For any questions about the study or the survey, please contact the RAND Europe Project Lead, Julia Muravska (muravska@randeurope.org).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
AI Continent Deployment: Best use of technologies
The European Commission has published the recording and presentations from its 18 December 2025 info session on the call topics Data Space for Manufacturing (DIGITAL-2026-DSM-AI-09-DS-MANUFACTUR-STEP) and European Digital Media Observatory hubs (DIGITAL-2026-BESTUSE-TECH-EDMO-09-HUBS). The slides and recording are available on ... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
